Ibudilast 20mg + Ibudilast 50mg + Placebo oral tablet

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 19/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Methamphetamine-dependence

Conditions

Methamphetamine-dependence, Substance Abuse

Trial Timeline

Jan 1, 2011 → Mar 1, 2013

NCT ID

NCT01217970

About Ibudilast 20mg + Ibudilast 50mg + Placebo oral tablet

Ibudilast 20mg + Ibudilast 50mg + Placebo oral tablet is a phase 1 stage product being developed by MediciNova for Methamphetamine-dependence. The current trial status is completed. This product is registered under clinical trial identifier NCT01217970. Target conditions include Methamphetamine-dependence, Substance Abuse.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01217970	Phase 1	Completed	Jan 1, 2011	Mar 1, 2013	Methamphetamine-dependence